Goldman Sachs
AVBP icon

Goldman Sachs’s ArriVent BioPharma AVBP Stock Holding History

Goldman Sachs’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$29.7M Buy
853,723
+296
+0% +$8.74K ﹤0.01% 2271
2026
Q1 		$19.7M Buy
853,427
+110,901
+15% +$2.5M ﹤0.01% 2450
2025
Q4 		$14.9M Buy
742,526
+310,587
+72% +$6.46M ﹤0.01% 2663
2025
Q3 		$7.97M Buy
431,939
+92,743
+27% +$1.82M ﹤0.01% 3194
2025
Q2 		$7.38M Buy
339,196
+262,319
+341% +$5.45M ﹤0.01% 3047
2025
Q1 		$1.42M Sell
76,877
-130,392
-63% -$3.19M ﹤0.01% 4421
2024
Q4 		$5.52M Buy
207,269
+134,301
+184% +$3.86M ﹤0.01% 3353
2024
Q3 		$1.71M Buy
+72,968
New +$1.66M ﹤0.01% 4281

Other funds holding AVBP

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $983M AUM 26.53% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Goldman Sachs's AVBP Position: Q2 2026 in Review

Goldman Sachs increased its ArriVent BioPharma (AVBP) stake by 0.03% in Q2 2026, buying an estimated $8.74K and bringing the position to 853,723 shares worth $29.7M. The position accounts for ﹤0.01% of the portfolio, ranked #2271.

Goldman Sachs first reported a position in AVBP in Q3 2024 and has held it in 8 quarters since. 157 funds tracked by Wall St. Rank hold AVBP as of Q2 2026.

  • Goldman Sachs held 853,723 shares of ArriVent BioPharma worth $29.7M as of Q2 2026.
  • Goldman Sachs bought 296 ArriVent BioPharma shares in Q2 2026, an estimated $8.74K.
  • ArriVent BioPharma made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #2271 holding.
  • Goldman Sachs first reported a position in ArriVent BioPharma in Q3 2024 and has held it in 8 quarters since.
  • 157 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.